Literature DB >> 33402361

Inflammation Mediates the Development of Aggressive Breast Cancer Following Radiotherapy.

Lin Ma1, Alba Gonzalez-Junca1, Yufei Zheng1, Haoxu Ouyang2, Irineu Illa-Bochaca2, Kathleen C Horst3, Gregor Krings4, Yinghao Wang1, Ignacio Fernandez-Garcia2, William Chou1, Mary Helen Barcellos-Hoff5.   

Abstract

PURPOSE: Women treated with radiotherapy before 30 years of age have increased risk of developing breast cancer at an early age. Here, we sought to investigate mechanisms by which radiation promotes aggressive cancer. EXPERIMENTAL
DESIGN: The tumor microenvironment (TME) of breast cancers arising in women treated with radiotherapy for Hodgkin lymphoma was compared with that of sporadic breast cancers. To investigate radiation effects on carcinogenesis, we analyzed tumors arising from Trp53-null mammary transplants after irradiation of the target epithelium or host using immunocompetent and incompetent mice, some of which were treated with aspirin.
RESULTS: Compared with age-matched specimens of sporadic breast cancer, radiation-preceded breast cancers (RP-BC) were characterized by TME rich in TGFβ, cyclooxygenase 2, and myeloid cells, indicative of greater immunosuppression, even when matched for triple-negative status. The mechanism by which radiation impacts TME construction was investigated in carcinomas arising in mice bearing Trp53-null mammary transplants. Immunosuppressive TMEs (iTME) were recapitulated in mice irradiated before transplantation, which implicated systemic immune effects. In nu/nu mice lacking adaptive immunity irradiated before Trp53-null mammary transplantation, cancers also established an iTME, which pointed to a critical role for myeloid cells. Consistent with this, irradiated mammary glands contained more macrophages and human cells cocultured with polarized macrophages underwent dysplastic morphogenesis mediated by IFNγ. Treating mice with low-dose aspirin for 6 months postirradiation prevented establishment of an iTME and resulted in less aggressive tumors.
CONCLUSIONS: These data show that radiation acts via nonmutational mechanisms to promote markedly immunosuppressive features of aggressive, RP-BCs. ©2021 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2021        PMID: 33402361      PMCID: PMC7956216          DOI: 10.1158/1078-0432.CCR-20-3215

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   13.801


  67 in total

Review 1.  Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer.

Authors:  Brian Bierie; Harold L Moses
Journal:  Nat Rev Cancer       Date:  2006-07       Impact factor: 60.716

Review 2.  How do tissues respond to damage at the cellular level? The role of cytokines in irradiated tissues.

Authors:  M H Barcellos-Hoff
Journal:  Radiat Res       Date:  1998-11       Impact factor: 2.841

3.  Transforming growth factor type beta induces monocyte chemotaxis and growth factor production.

Authors:  S M Wahl; D A Hunt; L M Wakefield; N McCartney-Francis; L M Wahl; A B Roberts; M B Sporn
Journal:  Proc Natl Acad Sci U S A       Date:  1987-08       Impact factor: 11.205

4.  IL-2 induces expression and secretion of IFN-gamma in murine peritoneal macrophages.

Authors:  Patrizia Puddu; Maria Carollo; Immacolata Pietraforte; Francesca Spadaro; Marina Tombesi; Carlo Ramoni; Filippo Belardelli; Sandra Gessani
Journal:  J Leukoc Biol       Date:  2005-06-10       Impact factor: 4.962

5.  Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.

Authors:  Carsten Denkert; Gunter von Minckwitz; Silvia Darb-Esfahani; Bianca Lederer; Barbara I Heppner; Karsten E Weber; Jan Budczies; Jens Huober; Frederick Klauschen; Jenny Furlanetto; Wolfgang D Schmitt; Jens-Uwe Blohmer; Thomas Karn; Berit M Pfitzner; Sherko Kümmel; Knut Engels; Andreas Schneeweiss; Arndt Hartmann; Aurelia Noske; Peter A Fasching; Christian Jackisch; Marion van Mackelenbergh; Peter Sinn; Christian Schem; Claus Hanusch; Michael Untch; Sibylle Loibl
Journal:  Lancet Oncol       Date:  2017-12-07       Impact factor: 41.316

Review 6.  The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition.

Authors:  Priti S Hegde; Vaios Karanikas; Stefan Evers
Journal:  Clin Cancer Res       Date:  2016-04-15       Impact factor: 12.531

7.  Macrophages, more than just scavengers: their role in breast development and cancer.

Authors:  David E Gyorki; Geoffrey J Lindeman
Journal:  ANZ J Surg       Date:  2008-06       Impact factor: 1.872

8.  Induction of IFN-gamma in macrophages by lipopolysaccharide.

Authors:  M J Fultz; S A Barber; C W Dieffenbach; S N Vogel
Journal:  Int Immunol       Date:  1993-11       Impact factor: 4.823

9.  Pathologic evaluation of tumor-associated macrophage density and vessel inflammation in invasive breast carcinomas.

Authors:  Yoshihiro Morita; Roy Zhang; Macall Leslie; Smita Adhikari; Nafis Hasan; Inna Chervoneva; Hallgeir Rui; Takemi Tanaka
Journal:  Oncol Lett       Date:  2017-06-22       Impact factor: 2.967

10.  TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells.

Authors:  Sanjeev Mariathasan; Shannon J Turley; Dorothee Nickles; Alessandra Castiglioni; Kobe Yuen; Yulei Wang; Edward E Kadel; Hartmut Koeppen; Jillian L Astarita; Rafael Cubas; Suchit Jhunjhunwala; Romain Banchereau; Yagai Yang; Yinghui Guan; Cecile Chalouni; James Ziai; Yasin Şenbabaoğlu; Stephen Santoro; Daniel Sheinson; Jeffrey Hung; Jennifer M Giltnane; Andrew A Pierce; Kathryn Mesh; Steve Lianoglou; Johannes Riegler; Richard A D Carano; Pontus Eriksson; Mattias Höglund; Loan Somarriba; Daniel L Halligan; Michiel S van der Heijden; Yohann Loriot; Jonathan E Rosenberg; Lawrence Fong; Ira Mellman; Daniel S Chen; Marjorie Green; Christina Derleth; Gregg D Fine; Priti S Hegde; Richard Bourgon; Thomas Powles
Journal:  Nature       Date:  2018-02-14       Impact factor: 49.962

View more
  3 in total

1.  Innovative targets of the lncRNA-miR-mRNA network in response to low-dose aspirin in breast cancer patients.

Authors:  Sadaf Alipour; Solmaz Khalighfard; Vahid Khori; Taghi Amiriani; Mahboubeh Tajaldini; Mohammad Dehghan; Somayeh Sadani; Ramesh Omranipour; Gelareh Vahabzadeh; Bita Eslami; Ali Mohammad Alizadeh
Journal:  Sci Rep       Date:  2022-07-14       Impact factor: 4.996

2.  Tumor ENPP1 (CD203a)/Haptoglobin Axis Exploits Myeloid-Derived Suppressor Cells to Promote Post-Radiotherapy Local Recurrence in Breast Cancer.

Authors:  Borja Ruiz-Fernández de Córdoba; Haritz Moreno; Fernando Lecanda; Rafael Martínez-Monge; Karmele Valencia; Naiara Perurena; Pablo Ruedas; Thomas Walle; Alberto Pezonaga-Torres; Juan Hinojosa; Elisabet Guruceaga; Antonio Pineda-Lucena; Marta Abengózar-Muela; Denis Cochonneau; Carolina Zandueta; Susana Martínez-Canarias; Álvaro Teijeira; Daniel Ajona; Sergio Ortiz-Espinosa; Xabier Morales; Carlos Ortiz de Solórzano; Marta Santisteban; Luis I Ramos-García; Laura Guembe; Vratislav Strnad; Dominique Heymann; Sandra Hervás-Stubbs; Rubén Pío; María E Rodríguez-Ruiz; Carlos E de Andrea; Silvestre Vicent; Ignacio Melero
Journal:  Cancer Discov       Date:  2022-05-02       Impact factor: 38.272

3.  RORα Suppresses Cancer-Associated Inflammation by Repressing Respiratory Complex I-Dependent ROS Generation.

Authors:  Wei Mao; Gaofeng Xiong; Yuanyuan Wu; Chi Wang; Daret St Clair; Jia-Da Li; Ren Xu
Journal:  Int J Mol Sci       Date:  2021-10-01       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.